Skip to main content

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Search

1143 result(s) found, displaying 351 to 375
  • Australian Public Assessment Report for Tucatinib
  • Australian Public Assessment Report for Trifarotene
  • Australian Public Assessment Report for Afamelanotide
  • Australian Public Assessment Report for Brexpiprazole
  • Australian Public Assessment Report for Insulin aspart
  • Australian Public Assessment Report for Nintedanib (as Esilate)
  • Australian Public Assessment Report for Etanercept
  • Australian Public Assessment Report for Opicapone
  • Australian Public Assessment Report for Secukinumab
  • Australian Public Assessment Report for Teriparatide
  • Australian Public Assessment Report for Cannabidiol
  • Australian Public Assessment Report for Iodised oil
  • Australian Public Assessment Report for Flucelvax Quad (quadrivalent influenza vaccine) for the prevention of of influenza in adults and children 9 years and older
  • Australian Public Assessment Report for Larotrectinib
  • Australian Public Assessment Report for Entrectinib
  • Australian Public Assessment Report for Voretigene neparvovec
  • AusPAR for Defitelio (defibrotide) for treatment of severe hepatic veno-occlusive disease in haematopoietic stem-cell transplantation.
  • New AusPAR for Dipeptiven (alanylglutamine) to treat patient in hypercatabolic and/or hypermetabolic states as part of parenteral nutrition.
  • AusPAR for Mvasi (bevacizumab) for treatment of various cancers
  • Australian Public Assessment Report for Ozanimod hydrochloride